CTT Pharma wins US patent for micelle-based nicotine, vitamins, caffeine delivery technology

Reuters2026/08/12 11:40

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

CTT Pharmaceutical Holdings won a U.S. patent for a continuation-in-part covering micelle delivery technology for nicotine, vitamins, caffeine.
Patent issuance is scheduled for Aug. 11, 2026, with a patent number already assigned by the U.S. Patent Office.
Coverage supports use in dissolvable oral formats such as strips, gum, pouches, lozenges, dissolving tablets.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CTT Pharmaceutical Holdings Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001171520-26-000225), on August 12, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

CTT Pharma wins US patent for micelle-based nicotine, vitamins, caffeine delivery technology

You may also like

Crypto prices